Abstract: The present invention provides an engineered clostridial toxin comprising at least one amino acid modification, wherein said at least one amino acid modification increases the isoelectric point (pI) of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the pI of an otherwise identical clostridial toxin lacking said at least one amino acid modification. Also provided are corresponding uses of the engineered clostridial toxin in therapy.

Abstract: Method for preventing or treating a condition or disease in a subject comprising administering to the subject an engineered clostridial toxin comprising at least one amino acid modification that increases the isoelectric point of the toxin to a value that is at least 0.2 pI units higher than the isoelectric point of an otherwise identical clostridial toxin lacking the modification.

Abstract: A fastener includes a main body having a tubular portion and a split portion that extends from a lower end of the tubular portion, and longitudinally includes a tapered section that tapers in a direction towards the tubular portion. The fastener further includes an expansion sleeve annularly surrounding the split portion, wherein the expansion sleeve longitudinally extends to a lower end of the tapered section.

Abstract: The present invention relates to a method for forming silica nanoparticles in an aqueous medium, the method comprising steps of providing a surfactant solution comprising a cationic surfactant in an aqueous medium; and mixing a silane source with the surfactant solution under pH conditions of about pH 5 to 8 for forming said silica nanoparticles. The present invention also relates to silica suspension comprising a plurality of hexagonally shaped silica platelets, said platelets being substantially monodisperse and having a width dimension from around 50 to 1000 nm, said platelets being suspended in an aqueous medium, wherein said aqueous medium comprises a single type of cationic surfactant. Furthermore, the invention relates to a silica nanoparticle prepared by reacting a silane source with a volumetric excess of a surfactant under pH of about 5 to about 8 in the presence of an aqueous solvent. Also, the present invention relates to a silica platelet obtainable by a method as disclosed herein.

Abstract: An automated masking system includes a substrate loading apparatus designed to hold a plurality of substrates, a first masking material application station designed to automatically apply a first masking material to a portion of the substrate, and a second masking material application station designed to automatically apply a second masking material to a portion of the substrate, the second masking material being different than the first masking material. The system includes a first dispensing apparatus and a second dispensing apparatus that move relative to the substrate in a repeatable motion. The substrate moves automatically from the first masking material application station to the second masking material application station.

Abstract: Systems and methods for variant calling in single molecule sequencing from a genomic dataset using a convolutional deep neural network. The method includes: transforming properties of each of the variants into a multi-dimensional tensor; passing the multi-dimensional tensors through a trained convolutional deep neural network to predict categorical output variables, the convolutional deep neural network minimizing a cost function iterated over each variant, the convolutional deep neural network trained using a training genomic dataset including previously identified variants, the convolutional neural network including: a plurality of pooled convolutional layers and at least two fully-connected layers connected sequentially after the last of the pooled convolutional layers, the at least two fully-connected layers comprising a second fully-connected layer connected sequentially after a first fully-connected layer; and outputting the predicted categorical output variables.

Abstract: Method for preventing or treating a condition or disease in a subject comprising administering to the subject an engineered clostridial toxin comprising at least one amino acid modification that increases the isoelectric point of the toxin to a value that is at least 0.2 pI units higher than the isoelectric point of an otherwise identical clostridial toxin lacking the modification.

Abstract: Engineered clostridial toxins comprising an amino acid modification that increases the isoelectric point of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the isoelectric point of an otherwise identical clostridial toxin lacking the modification, wherein the modification is not located in the clostridial toxin binding domain (HC domain).

Abstract: Embodiments of the present disclosure discloses a temperature detecting device, a temperature detecting system and a temperature detecting method. The temperature detecting device includes: a bearing support, a first end of the bearing support being fixed; a temperature detector, provided on a second end of the bearing support; a moving component, configured to be connected with the bearing support, wherein the second end of the bearing support is movable with respect to the first end under driving of the moving component.

Abstract: The invention provides methods for producing soluble di-chain BoNT/A protein.

Abstract: Methods for producing di-chain BoNT/A from single chain BoNT/A using Lys-C followed by purification using a hydrophobic surface.

Abstract: The present invention relates to chimeric neurotoxins with enhanced properties and their use in therapy.

Abstract: A noninvasive arterial condition detecting system includes a processing device and an electronic stethoscope configured for auscultating carotid artery to receive sound signals. The processing device is connected to the electronic stethoscope. The processing device records the sound signals, preprocesses the sound signal to reduce noise, measures a trough-peak distance and a trough-peak time, and generates an estimate result of arterial conditions according to the trough-peak distance and the trough-peak time. The trough-peak distance and the trough-peak time are related to the health of the carotid artery walls.

Abstract: The present invention provides an engineered clostridial toxin comprising at least one amino acid modification, wherein said at least one amino acid modification increases the isoelectric point (pI) of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the pI of an otherwise identical clostridial toxin lacking said at least one amino acid modification. Also provided are corresponding uses of the engineered clostridial toxin in therapy.

Abstract: Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.

Abstract: Engineered clostridial toxins comprising an amino acid modification that increases the isoelectric point of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the isoelectric point of an otherwise identical clostridial toxin lacking the modification, wherein the modification is not located in the clostridial toxin binding domain (HC domain).

Abstract: The invention provides methods for producing soluble di-chain BoNT/A protein.

Abstract: An automated masking system includes a substrate loading apparatus designed to hold a plurality of substrates, a first masking material application station designed to automatically apply a first masking material to a portion of the substrate, and a second masking material application station designed to automatically apply a second masking material to a portion of the substrate, the second masking material being different than the first masking material. The system includes a first dispensing apparatus and a second dispensing apparatus that move relative to the substrate in a repeatable motion. The substrate moves automatically from the first masking material application station to the second masking material application station.

Abstract: The present invention provides an engineered clostridial toxin comprising at least one amino acid modification, wherein said at least one amino acid modification increases the isoelectric point (pI) of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the pI of an otherwise identical clostridial toxin lacking said at least one amino acid modification. Also provided are corresponding uses of the engineered clostridial toxin in therapy.

Abstract: There is provided a core-shell particle having pores extending through its shell and a plurality of polymers that are bonded to the outer surface of the shell, wherein the polymers are comprised of repeating monomer units of formula (1): [Formula should be inserted here] wherein the substituents are as defined herein. There is also provided a method of synthesizing the core-shell particle and use of the core-shell particle as a delivery agent.